Chen, Yi-WeiYi-WeiChenLee, Yi-YenYi-YenLeeLin, Chun-FuChun-FuLinPan, Po-ShenPo-ShenPanChen, Jen-KunJen-KunChenCHUN-WEI WANGHsu, Shih-MingShih-MingHsuKuo, Yu-ChengYu-ChengKuoLan, Tien-LiTien-LiLanHsu, Sanford P CSanford P CHsuLiang, Muh-LiiMuh-LiiLiangChen, Robert Hsin-HungRobert Hsin-HungChenChang, Feng-ChiFeng-ChiChangWu, Chih-ChunChih-ChunWuLin, Shih-ChiehShih-ChiehLinLiang, Hsiang-KuangHsiang-KuangLiangLee, Jia-ChengJia-ChengLeeChen, Shih-KuanShih-KuanChenLiu, Hong-MingHong-MingLiuPeir, Jinn-JerJinn-JerPeirLin, Ko-HanKo-HanLinHuang, Wen-ShengWen-ShengHuangChen, Kuan-HsuanKuan-HsuanChenKang, Yu-MeiYu-MeiKangLiou, Shueh-ChunShueh-ChunLiouWang, Chun-ChiehChun-ChiehWangPai, Ping-ChingPing-ChingPaiLi, Chih-WeiChih-WeiLiChiek, Daniel Quah SongDaniel Quah SongChiekWong, Tai-TongTai-TongWongChiou, Shih-HwaShih-HwaChiouChao, YeeYeeChaoTanaka, HirokiHirokiTanakaChou, Fong-InFong-InChouHSIANG-KUANG LIANG et al.2021-12-172021-12-172021-04-152079-7737https://scholars.lib.ntu.edu.tw/handle/123456789/590115Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan-Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.enBNCT; T/B ratio; T/N ratio; glioblastoma; radioresistance[SDGs]SDG3journal article10.3390/biology10040334339209842-s2.0-85104952726https://scholars.lib.ntu.edu.tw/handle/123456789/561678